Physician profile
Bridget Gessler
NPI 1447312103
$558.46
in general payments reported to CMS, 2019-2025
11 companies · $315 in 2025
The $315 reported for 2025 was less than what a typical Psychiatric/Mental Health, Child & Adolescent (Clinical Nurse Specialist) provider received nationally (typical 2025 total: $315).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $47.81 · 2024: $196 · 2025: $315.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $558.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $558.46 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Supernus Pharmaceuticals, INC. | $264.40 | 2024-2025 | Qelbree |
| Abbvie INC. | $49.11 | 2024-2025 | |
| Collegium Pharmaceutical, INC. | $37.92 | 2025 | Jornay Pm |
| E.R. Squibb & Sons, L.L.C. | $36.04 | 2025 | Cobenfy |
| Takeda Pharmaceuticals U.S.A., INC. | $35.92 | 2023-2025 | Trintellix |
| Otsuka America Pharmaceutical, INC. | $32.96 | 2025 | Rexulti |
| Alkermes, INC. | $29.53 | 2025 | Aristada, Lybalvi |
| Corium, LLC | $28.40 | 2023-2024 | Azstarys |
| Bausch Health US, LLC | $15.80 | 2023 | Aplenzin |
| Noven Therapeutics, LLC | $14.81 | 2024 | Xelstrym |
| Lundbeck LLC | $13.57 | 2024 | Rexulti |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Bridget Gessler listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.